Skip to main content
. 2021 May 11;26(7):562–568. doi: 10.1002/onco.13806

Figure 2.

Figure 2

Kaplan‐Meier comparisons of PFS by pretreatment patient‐reported physical function for the randomized arms of MONARCH 2 and MONARCH 3 (abemaciclib vs. comparator). Abbreviations: NSAI, nonsteroidal aromatase inhibitor; PFS, progression‐free survival.